MYC and neuroendocrine neoplasm: Taken together, our results suggest that targeting the IGF2BP1-c-Myc-EZH2 network at various levels might be a promising therapeutic approach in neuroendocrine tumors, potentially also by using combinatorial approaches, warranting further in vivo validation.